Mega Genomics (SEHK:6667) Stock Price Meets A Harsh Margin Reality

Investors barely flinched at Mega Genomics on Tuesday, with the stock at HK$7.09 after a flat month and only a small move over the past quarter. The market reaction looks muted compared with the sharp squeeze in profitability that now defines the story. Trailing net profit margin has fallen to 6.8%, while the stock still trades on a P/E of 55.6x, above both healthcare peers and the Hong Kong industry average.

If you care about the next few days, that might feel fine. If you care about the next few years, the margin and valuation gap is the headline from these earnings.

Is Mega Genomics priced for a recovery or already stretched given its 6.8% margin, 55.6x P/E and a share price above DCF value? See how the valuation case stacks up in our valuation analysis for Mega Genomics

H1 2026 Earnings Summary

• Revenue, H1 2026 vs. H1 2025: ¥192.499 million vs. ¥81.281 million (change in scale of revenue base year on year)
• Net Income, H1 2026 vs. H1 2025: ¥24.751 million vs. ¥27.261 million (decline in net earnings)
• Basic EPS, H1 2026 vs. H1 2025: ¥0.12 per share vs. ¥0.133352 per share (decline in earnings per share)
• Trailing Net Profit Margin, last 12 months vs. prior 12 months: 6.8% vs. 25.6% (sharp margin compression)

Prefer clean charts instead of another wall of earnings tables and raw figures? See Mega Genomics' full visual story, including how its valuation, margins and earnings profile line up in context, in our company report for Mega Genomics.

Mega Genomics: Revenue Scale Backs Growth Story

Mega Genomics now reports H1 2026 revenue of ¥192.499 million against ¥81.281 million in H1 2025. For a genomics platform built around cancer screening and brain health testing, this larger top line backs the idea that market demand for its portfolio is broadening. Even with a smaller H1 net income of ¥24.751 million versus ¥27.261 million and softer basic EPS, the business still converts part of its larger revenue base into profit, which keeps the long term precision medicine narrative alive.

Profitability Compression Tests Bullish Narrative

The bearish read on Mega Genomics focuses on profitability and earnings quality. Trailing net profit margin moved from 25.6% to 6.8%. Net income and basic EPS in H1 2026 are both below H1 2025. That combination raises questions about pricing power, mix and cost control just as the story leans on high value cancer and neurodegenerative testing. The recent share price drift, with returns slightly down over 7 and 30 days, suggests investors are treating the growth story more cautiously after these results.

After years of softer earnings and a margin drop from 25.6% to 6.8%, it is fair to ask whether Mega Genomics is facing one off pressure or something more structural. Review our independent risk analysis for Mega Genomics which shows 2 important warning signs

Take Control Of Your Next Move

If Mega Genomics looks interesting after its sharp margin compression and premium 55.6x P/E, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and wait for an entry point that fits your plan. When you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on the updates that really affect your holdings. For a longer term view, tap into the Community to see how other investors are thinking about the same risks and potential catalysts. That way you can spot hidden strengths and pressure points early and stay a step ahead of the market.

Seeking Alternatives Beyond Mega Genomics?

Fresh ideas move fast. Some stocks are building quiet momentum, others are close to a breakout, and a few could be dropping off the radar. Check them while it matters and get in early.

• Spot resilient income opportunities before yields get compressed and review a curated group of 417 dividend fortresses that aim to balance reliable payouts with balance sheet strength.
• Hunt for potential growth stories still flying under the radar and scan a focused mix of 616 high quality undiscovered gems that pair solid fundamentals with overlooked market attention.
• Zero in on sturdier balance sheets while valuations still look reasonable and work through a refined list of solid balance sheet and fundamentals stocks (437 results) that filters for financial strength and quality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com